Ficlatuzumab

Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers. Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing gefitinib alone and in combination with ficlatuzamab in treatment-naive Asian patients with non-small cell lung cancer.

Ficlatuzumab

Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers. Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing gefitinib alone and in combination with ficlatuzamab in treatment-naive Asian patients with non-small cell lung cancer.